Susquehanna International Group’s aTyr Pharma ATYR Stock Holding History

Susquehanna International Group’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$127K	Sell	162,900 -13,600	-8%	-$11.5K	﹤0.01%	12168
2025 Q4	$138K	Sell	176,500 -9,900	-5%	-$8.13K	﹤0.01%	11244
2025 Q3	$134K	Buy	186,400 +66,900	+56%	+$303K	﹤0.01%	11369
2025 Q2	$606K	Buy	119,500 +35,400	+42%	+$139K	﹤0.01%	8730
2025 Q1	$254K	Buy	84,100 +73,200	+672%	+$267K	﹤0.01%	10436
2024 Q4	$39.5K	Buy	+10,900	New	+$33K	﹤0.01%	11768
2023 Q3	–	Sell	-55,100	Closed	-$119K	–	13170
2023 Q2	$119K	Buy	+55,100	New	+$120K	﹤0.01%	10805
2022 Q4	–	Sell	-98,400	Closed	-$295K	–	13887
2022 Q3	$295K	Sell	98,400 -11,300	-10%	-$37.9K	﹤0.01%	9839
2022 Q2	$310K	Buy	109,700 +2,600	+2%	+$9.4K	﹤0.01%	9485
2022 Q1	$573K	Buy	107,100 +76,900	+255%	+$436K	﹤0.01%	8627
2021 Q4	$226K	Sell	30,200 -13,500	-31%	-$113K	﹤0.01%	11191
2021 Q3	$397K	Buy	+43,700	New	+$261K	﹤0.01%	9962

Other funds holding ATYR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group's ATYR Position: Q1 2026 in Review

Susquehanna International Group increased its aTyr Pharma (ATYR) stake by 13% in Q1 2026, buying an estimated $86.1K and bringing the position to 866,744 shares worth $676K. The position accounts for ﹤0.01% of the portfolio, ranked #8884.

Susquehanna International Group first reported a position in ATYR in Q1 2017 and has held it in 16 quarters since. The position peaked at $5.23M in Q1 2025. 111 funds tracked by Wall St. Rank hold ATYR as of Q1 2026.

Susquehanna International Group held 866,744 shares of aTyr Pharma worth $676K as of Q1 2026.
Susquehanna International Group bought 102,001 aTyr Pharma shares in Q1 2026, an estimated $86.1K.
aTyr Pharma made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #8884 holding.
Susquehanna International Group first reported a position in aTyr Pharma in Q1 2017 and has held it in 16 quarters since.
Susquehanna International Group's aTyr Pharma position peaked at $5.23M in Q1 2025.
111 funds tracked by Wall St. Rank held aTyr Pharma as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.